1:45PM – 2:30PM
KEYNOTE From “Most Admired” to “Pharma Bros”: How Biopharmaceutical Companies Have Allowed the Debate on Drug Pricing to Steal Their Reputation – and What Communications Professionals Can Do to Help Get It Back
Ron Cohen, M.D., Founder, Chief Executive Officer and President, ACORDA THERAPEUTICS
Interviewed by: Tierney Saccavino, Executive Vice President, Corporate Communications, ACORDA THERAPEUTICS
In the 1980s and 1990s, Merck was ranked the most admired company in America seven years in a row. Compare that to today’s headlines: “Drug price strategy enriches company, but infuriates patients and lawmakers,” “Cancer patient, outraged by sky-high drug prices, organizes others to fight them,” “Drug goes from $13.50 a tablet to $750, overnight.” The biopharmaceutical industry is in a crisis and must take action to regain its credibility and reputation.
Join Dr. Cohen in a moderated discussion in which he provides his insights on where industry pricing models are heading, the potential for legislative action, and what companies must do to reestablish trust with the public and patient communities they serve.